
Claims

1. A combination of a proteasome inhibitor, wherein said proteasome inhibitor is bortezomib, and a histone deacetylase inhibitor wherein said histone deacetylase inhibitor is compound No. 1a (JNJ26481585).



Compound No 1a

the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof.


2. A combination as claimed in claim 1 in the form of a pharmaceutical composition comprising bortezomib and compound No. 1a together with one or more pharmaceutical carriers.

3. A combination as claimed in claim 2 for simultaneous, separate or sequential use.

4. A combination as claimed in any of claims 1 to 3 for use in medical therapy.

5. Use of a combination as claimed in any of claims 1 or 2 for the manufacture of a medicament for inhibiting the growth of tumor cells.

6. Use of a histone deacetylase inhibitor in combination with a proteasome inhibitor, for the manufacture of a medicament for the treatment of acute lymphoblastic leukemia, acute myelogenous leukemia, acute promyelocytic leukemia, acute myeloid leukemia, acute monocytic leukemia, lymphoma, chronic B cell leukemia, chronic myeloid leukemia, chronic myeloid leukemia in blast crisis, Burkitt's lymphoma and multiple myeloma wherein said histone deactylase inhibitor is compound No. 1a



Compound No 1a

the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof,


and wherein said proteasome inhibitor is bortezomib.

7. Use as claimed in claim 6 wherein said medicament is for treatment of drug resistant acute lymphoblastic leukemia, drug resistant acute myelogenous leukemia, drug resistant acute promyelocytic leukemia, drug resistant acute myeloid leukemia, drug resistant acute monocytic leukemia, drug resistant lymphoma, drug resistant chronic B cell leukemia, drug resistant chronic myeloid leukemia, drug resistant chronic myeloid leukemia in blast crisis, drug resistant Burkitt's lymphoma and drug resistant multiple myeloma.

8. Use as claimed in claims 6 and 7 wherein said medicament is for treatment of bortezomib resistant multiple myeloma.

Claims

1. A combination of a proteasome inhibitor, wherein said proteasome inhibitor is bortezomib, and a histone deacetylase inhibitor wherein said histone deacetylase inhibitor is compound No. 1a (JNJ26481585)



Compound No 1a

the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof.


2. A combination as claimed in claim 1 in the form of a pharmaceutical composition comprising bortezomib and compound No. 1a together with one or more pharmaceutical carriers.

3. A combination as claimed in claim 2 for simultaneous, separate or sequential use.

4. A combination as claimed in any of claims 1 to 3 for use in medical therapy.

5. Use of a combination as claimed in any of claims 1 or 2 for the manufacture of a medicament for inhibiting the growth of tumor cells.

6. Use of a histone deacetylase inhibitor in combination with a proteasome inhibitor, for the manufacture of a medicament for the treatment of acute lymphoblastic leukemia, acute myelogenous leukemia, acute promyelocytic leukemia, acute myeloid leukemia, acute monocytic leukemia, lymphoma, chronic B cell leukemia, chronic myeloid leukemia, chronic myeloid leukemia in blast crisis, Burkitt's lymphoma and multiple myeloma wherein said histone deactylase inhibitor is compound No. 1a



Compound No 1a

the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof,

and wherein said proteasome inhibitor is bortezomib.

7. Use as claimed in claim 6 wherein said medicament is for treatment of drug resistant acute lymphoblastic leukemia, drug resistant acute myelogenous leukemia, drug resistant acute promyelocytic leukemia, drug resistant acute myeloid leukemia, drug resistant acute monocytic leukemia, drug resistant lymphoma, drug resistant chronic B cell leukemia, drug resistant chronic myeloid leukemia, drug resistant chronic myeloid leukemia in blast crisis, drug resistant Burkitt's lymphoma and drug resistant multiple myeloma.

8. Use as claimed in claims 6 and 7 wherein said medicament is for treatment of bortezomib resistant multiple myeloma.